Plasma and plasma components in the management of disseminated intravascular coagulation

Best Practice and Research: Clinical Haematology

Volumn 19, Issue 1, 2006, Pages 127-142

  Levi, Marcel ^a   de Jonge, Evert ^a   van der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Antithrombin; Disseminated intravascular coagulation; Fibrinolysis; Inflammation; Plasminogen activator inhibitor; Protein c; Sepsis; Thrombin; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR CONCENTRATE; BLOOD DERIVATIVE; DROTRECOGIN; HEPARIN; INTERLEUKIN 1; INTERLEUKIN 6; PLACEBO; PLASMA PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; PROTHROMBIN COMPLEX; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; AUTOPSY; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG RECEPTOR BINDING; EXPERIMENTAL STUDY; FIBRIN DEPOSITION; FIBRINOLYSIS; HUMAN; MICROANGIOPATHY; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; SEPSIS; STRATEGIC PLANNING; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

ANTICOAGULANTS; BLOOD COMPONENT TRANSFUSION; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; PLASMA;

EID: 31044439009     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.01.027     Document Type: Review

References (79)

1. K.A. Bauer & R.D. Rosenberg The pathophysiology of the prethrombotic state in humans: Insights gained from studies using markers of hemostatic system activation Blood 70 1987 343-350
2. M. Levi & H. ten Cate Disseminated intravascular coagulation N Engl J Med 341 1999 586-592
3. M. Levi Current understanding of disseminated intravascular coagulation Br J Haematol 124 2004 567-576
4. D.I. Feinstein Diagnosis and management of disseminated intravascular coagulation: The role of heparin therapy Blood 60 1982 284-287
5. H.P. Schwarz M. Fischer P. Hopmeier M.A. Batard & J.H. Griffin Plasma protein S deficiency in familial thrombotic disease Blood 64 1984 1297-1300
6. O.D. Ratnoff & W.G. Nebehay Multiple coagulative defects in a patient with the Waterhouse-Friderichsen syndrome Ann Intern Med 56 1962 627
7. M. Levi H. ten Cate & T. van der Poll Disseminated intravascular coagulation: State of the art Thromb Haemost 82 1999 695-705
8. A.P. Wheeler & G.R. Bernard Treating patients with severe sepsis N Engl J Med 340 1999 207-214
9. J. Hambleton L.L. Leung & M. Levi Coagulation: Consultative hemostasis Hematology (Am Soc Hematol Educ Program) 2002 335-352
10. K. Shimamura K. Oka M. Nakazawa & M. Kojima Distribution patterns of microthrombi in disseminated intravascular coagulation Arch Pathol Lab Med 107 1983 543-547
11. A.A. Creasey A.C. Chang L. Feigen T.C. Wun F.B.J. Taylor et al. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock J Clin Invest 91 1993 2850-2856
12. C.M. Kessler Z. Tang H.M. Jacobs & L.M. Szymanski The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity Blood 89 1997 4393-4401
13. F. Fourrier C. Chopin J. Goudemand et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies Chest 101 1992 816-823
14. W. Ruf & T.S. Edgington Structural biology of tissue factor, the initiator of thrombogenesis in vivo FASEB Journal 8 1994 385-390
15. K.G. Mann C. van't Veer K. Cawthern & S. Butenas The role of the tissue factor pathway in initiation of coagulation Blood Coagul Fibrinolys 9 supplement 1 1998 S3-S7
16. E. Camerer A.B. Kolsto & H. Prydz Cell biology of tissue factor, the principal initiator of blood coagulation Thromb Res 81 1996 1-41
17. D.W. Banner A. D'Arcy C. Chene et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor Nature 380 1996 41-46
18. H ten Cate K.A. Bauer M. Levi et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor J Clin Invest 92 1993 1207-1212
19. K.A. Bauer B.L. Kass C.H. ten J.J. Hawiger & R.D. Rosenberg Factor IX is activated in vivo by the tissue factor mechanism Blood 76 1990 731-736
20. R.F. Franco E. De Jonge P.E. Dekkers et al. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: Relationship with activation of coagulation Blood 96 2000 554-559
21. B. Osterud Tissue factor expression by monocytes: Regulation and pathophysiological roles Blood Coagul Fibrinolysis 9 supplement 1 1998 S9-S14
22. F.J. Neumann N. Marx M. Gawaz et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets Circulation 95 1997 2387-2394
23. P.L. Giesen U. Rauch B. Bohrmann et al. Blood-borne tissue factor: another view of thrombosis Proc Natl Acad Sci USA 96 1999 2311-2315
24. B. Osterud L.V. Rao & J.O. Olsen Induction of tissue factor expression in whole blood-lack of evidence for the presence of tissue factor expression on granulocytes Thromb Haemost 83 2000 861-867
25. W.C. Aird Vascular bed-specific hemostasis: Role of endothelium in sepsis pathogenesis Crit Care Med 29 2001 S28-S34
26. K.G. Mann Biochemistry and physiology of blood coagulation Thromb Haemost 82 1999 165-174
27. T. Koyama K. Nishida S. Ohdama et al. Determination of plasma tissue factor antigen and its clinical significance Br J Haematol 87 1994 343-347
28. R.M. Mesters P.M. Mannucci R. Coppola T. Keller H. Ostermann et al. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients Blood 88 1996 881-886
29. M. Jochum S. Lander N. Heimburger & H. Fritz Effect of human granulocytic elastase on isolated human antithrombin III Hoppe-Seylers Zeitschrift fur Physiologische Chemie 362 1981 103-112
30. M.C. Bourin & U. Lindahl Glycosaminoglycans and the regulation of blood coagulation Biochem J 289 1993 313-330
31. M. Kobayashi K. Shimada & T. Ozawa Human recombinant interleukin-1 beta- and tumor necrosis factor alpha-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells J Cell Physiol 144 1990 383-390
32. F.B.J. Taylor A.C. Chang G.T. Peer et al. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage Blood 78 1991 364-368
33. M.C. Minnema A.C. Chang P.M. Jansen et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli Blood 95 2000 1117-1123
34. C.T. Esmon The roles of protein C and thrombomodulin in the regulation of blood coagulation J Biol Chem 264 1989 4743-4746
35. B.N. Bouma & J.C. Meijers Fibrinolysis and the contact system: A role for factor XI in the down-regulation of fibrinolysis Thromb Haemost 82 1999 243-250
36. C.T. Esmon J. Xu J.M. Gu et al. Endothelial protein C receptor Thromb Haemost 82 1999 251-258
37. P. Gresele S. Momi M. Berrettini et al. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation J Clin Invest 101 1998 667-676
38. W.W. Hancock A. Tsuchida H. Hau N.M. Thomson & H.H. Salem The anticoagulants protein C and protein S display potent antiinflammatory and immunosuppressive effects relevant to transplant biology and therapy Transplant Proc 24 1992 2302-2303
39. Y. Taoka K. Okajima M. Uchiba et al. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes J Neurosci 18 1998 1393-1398
40. M. Uchiba K. Okajima K. Murakami et al. rhs-TM prevents ET-induced increase in pulmonary vascular permeability through protein C activation Am J Physiol 273 1997 L889-L894
41. F.B.J. Taylor B. Dahlback A.C. Chang et al. Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli Blood 86 1995 2642-2652
42. F.B.J. Taylor D.J. Stearns-Kurosawa S. Kurosawa et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis Blood 95 2000 1680-1686
43. F.B.J. Taylor A. Chang C.T. Esmon et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon J Clin Invest 79 1987 918-925
44. M. Levi J. Dorffler-Melly P.H. Reitsma et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein C deficient mice Blood 101 2003 4823-4827
45. P.P. Nawroth & D.M. Stern Modulation of endothelial cell hemostatic properties by tumor necrosis factor J Exp Med 163 1986 740-745
46. G.J. Broze Jr Tissue factor pathway inhibitor and the revised theory of coagulation Annu Rev Med 46 1995 103-112
47. W.F. Novotny S.G. Brown J.P. Miletich D.J. Rader & G.J. Broze Jr Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples Blood 78 1991 387-393
48. A. Ameri M.N. Kuppuswamy S. Basu & S.P. Bajaj Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators Blood 79 1992 3219-3226
49. P.M. Sandset B.J. Warn-Cramer L.V. Rao S.L. Maki & S.I. Rapaport Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant Proc Natl Acad Sci USA 88 1991 708-712
50. M.M. Randolph G.L. White S.D. Kosanke et al. Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli - a comparative study of treated and untreated non-surviving baboons challenged with LD100 E. coli Thromb Haemost 79 1998 1048-1053
51. C.T. Park A.A. Creasey & S.D. Wright Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14 Blood 89 1997 4268-4274
52. E. de Jonge P.E. Dekkers A.A. Creasey et al. Tissue factor pathway inhibitor (TFPI) dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia Blood 95 2000 1124-1129
53. M. Levi H. ten Cate K.A. Bauer et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees J Clin Invest 93 1994 114-120
54. B.J. Biemond P.W. Friederich M.L. Koschinsky et al. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo Circulation 96 1997 1612-1615
55. R.R. Schleef M.P. Bevilacqua M. Sawdey M.A.J. Gimbrone & D.J. Loskutoff Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor J Biol Chem 263 1988 5797-5803
56. M.S. Sawdey & D.J. Loskutoff Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta J Clin Invest 88 1991 1346-1353
57. K. Yamamoto & D.J. Loskutoff Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator J Clin Invest 97 1996 2440-2451
58. P.W. Hermans M.L. Hibberd R. Booy et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group Lancet 354 1999 556-560
59. R.G. Westendorp J.J. Hottenga & P.E. Slagboom Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock Lancet 354 1999 561-563
60. R.M. Mesters N. Florke H. Ostermann & J. Kienast Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis Thromb Haemost 75 1996 902-907
61. D.C. Altieri Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa J Biol Chem 269 1994 3139-3142
62. E. Camerer W. Huang & S.R. Coughlin Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa Proc Natl Acad Sci USA 97 2000 5255-5260
63. J.L. Degen Hemostatic factors and inflammatory disease Thromb Haemost 82 1999 858-864
64. S.R. Coughlin Thrombin signalling and protease-activated receptors Nature 407 2000 258-264
65. E. de Jonge P.W. Friederich M. Levi & T. van der Poll Activation of coagulation by administration of recombinant factor VIIa elcicits interleukin-6 and interleukin-8 release in healthy humen subjects Clin Diagn Lab Immunol 10 2003 495-497
66. C.T. Esmon Does inflammation contribute to thrombotic events? Haemostasis 30 supplement 2 2000 34-40
67. M. Levi E. de Jonge & T. van der Poll Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation Crit Care Med 29 supplement 7 2001 S90-S94
68. G.R. Bernard J.L. Vincent P.F. Laterre et al. Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 344 2001 699-709
69. S.J. Gross H.C. Filston & J.C. Anderson Controlled study of treatment for disseminated intravascular coagulation in the neonate J Pediatr 100 1982 445-448
70. H. du Toit A.R. Coetzee & D.O. Chalton Heparin treatment in thrombin-induced disseminated intravascular coagulation in the baboon Crit Care Med 19 1991 1195-1200
71. J. Dorffler-Melly E. de Jonge A.C. Pont et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors Lancet 359 2002 849-850
72. E. Abraham K. Reinhart P. Svoboda et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study Crit Care Med 29 2001 2081-2089
73. E. Abraham K. Reinhart S. Opal et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial JAMA 290 2003 238-247
74. B.L. Warren A. Eid P. Singer et al. Caring for the critically ill patient High-dose antithrombin III in severe sepsis: A randomized controlled trial JAMA 286 2001 1869-1878
75. F.B.J. Taylor A. Chang C.T. Esmon et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon J Clin Invest 79 1987 918-925
76. G.R. Bernard E.W. Ely T.J. Wright et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis Crit Care Med 29 2001 2051-2059
77. J.F. Dhainaut S.B. Yan D.E. Joyce et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation J Thromb Haemost 2 2004 1924-1933
78. J.L. Vincent D.C. Angus A. Artigas et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial Crit Care Med 31 2003 834-840
79. M. Levi Benefit of recombinant human activated protein C beyond 28-day mortality: There is more to life than death Crit Care Med 31 2003 984-985